Heterodimerization of FGF-receptor 1 and PDGF-receptor-α: A novel mechanism underlying the inhibitory effect of PDGF-BB on FGF-2 in human cells

Blood

Volumn 107, Issue 5, 2006, Pages 1896-1902

  Faraone, Debora ^b   Aguzzi, Maria S ^b   Ragone, Gianluca ^b   Russo, Katia ^b   Capogrossi, Maurizio C ^b   Facchiano, Antonio ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; HETERODIMER; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 6; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BB; PROTEIN CDC42; RAC1 PROTEIN; SYNAPTOPHYSIN;

ANIMAL CELL; ARTICLE; CELL FUNCTION; CELL LINE; CELL PROLIFERATION; CHEMICAL ANALYSIS; CONTROLLED STUDY; DIMERIZATION; ENDOTHELIUM CELL; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MITOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SWINE; UMBILICAL VEIN;

EID: 33344466472     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-04-1524     Document Type: Article

References (38)

1. Delrieu I. The high molecular weight isoforms of basic fibroblast growth factor (FGF-2): an insight into an intracrine mechanism. FEBS Lett. 2000;468:6-10.
2. Ornitz DM, Xu J, Colvin JS, et al. Receptor specificity of the fibroblast growth factor family. J Biol Chem. 1996;271:15292-15297.
3. Nugent MA, Iozzo RV. Fibroblast growth factor-2. Int J Biochem Cell Biol. 2000;32:115-120.
4. Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer. 2000;7:165-197.
5. Basilico C, Moscatelli D. The FGF family of growth factors and oncogenes. Adv Cancer Res. 1992;59:115-165.
6. Hou JZ, Kan MK, McKeehan K, McBride G, Adams P, McKeehan WL. Fibroblast growth factor receptors from liver vary in three structural domains. Science. 1991;251:665-668.
7. McKeehan WL, Hou JZ, Adams P, Wang F, Yan GC, Kan M. Heparin-binding fibroblast growth factors and prostate cancer. Adv Exp Med Biol. 1991;330:203-213.
8. Hoch RV, Soriano P. Roles of PDGF in animal development. Development. 2003;130:4769-4784.
9. Risau W, Drexler H, Mironov V, Smits A, Siegbahn A, Funa K, Heldin CH. Platelet-derived growth factor is angiogenic in vivo. Growth Factors. 1992;7:261-266.
10. Koyama N, Hart CE, Clowes AW. Different functions of the platelet-derived growth factor-alpha and -beta receptors for the migration and proliferation of cultured baboon smooth muscle cells. Circ Res. 1994;75:682-691.
11. Marx M, Perlmutter RA, Madri JA. Modulation of platelet-derived growth factor receptor expression in microvascular endothelial cells during in vitro angiogenesis. J Clin Invest. 1994;93:131-139.
12. Yokote K, Mori S, Siegbahn A, et al. Structural determinants in the platelet-derived growth factor alpha-receptor implicated in modulation of chemotaxis. J Biol Chem. 1996;271:5101-5111.
13. De Marchis F, Ribatti D, Giampietri C, et al. Platelet-derived growth factor inhibits basic fibroblast growth factor angiogenic properties in vitro and in vivo through its alpha receptor. Blood. 2002;99:2045-2053.
14. Russo K, Ragone R, Facchiano AM, Capogrossi MC, Facchiano A. Platelet-derived growth factor-BB and basic fibroblast growth factor directly interact in vitro with high affinity. J Biol Chem. 2002;277:1284-1291.
15. Clunn GF, Refson JS, Lymn JS, Hughes AD. Platelet-derived growth factor beta-receptors can both promote and inhibit chemotaxis in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1997;17:2622-2629.
16. Yu J, Liu XW, Kim HRC. Platelet-derived growth factor (PDGF) receptor-alpha-activated c-Jun NH2-terminal kinase-1 is critical for PDGF-induced p21WAF1/CIP1 promoter activity independent of p53. J Biol Chem. 2003;278:49582-49588.
17. Aguzzi MS, Giampietri C, De Marchis F, et al. RGDS peptide induces caspase 8 and caspase 9 activation in human endothelial cells. Blood. 2004;103:4180-4187.
18. Harris VK, Coticchia CM, Kagan BL, Ahmad S, Wellstein A, Riegel AT. Induction of the angiogenic modulator fibroblast growth factor-binding protein by epidermal growth factor is mediated through both MEK/ERK and p38 signal transduction pathways. J Biol Chem. 2000;275:10802-10811.
19. Mahadevan LC, Willis AC, Barratt MJ. Rapid histone H3 phosphorylation in response to growth factors, phorbol esters, okadaic acid, and protein synthesis inhibitors. Cell. 1991;655:775-783.
20. Hagedorn M, Zilberberg L, Lozano RM, et al. A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2. FASEB J. 2001;15:550-552.
21. Facchiano A, Russo K, Facchiano AM, et al. Identification of a novel domain of fibroblast growth factor 2 controlling its angiogenic properties. J Biol Chem. 2003;278:8751-8760.
22. Di Stasio E, Sciandra FG, Maras B, et al. Structural and functional analysis of the N-terminal extracellular region of beta-dystroglycan. Biochem Biophys Res Commun. 1999;266:274-278.
23. Emaduddin M, Ekman S, Ronnstrand L, Heldin CH. Functional co-operation between the subunits in heterodimeric platelet-derived growth factor receptor complexes. Biochem J. 1999;341:523-528.
24. Periasamy A, Day RN. Visualizing protein interactions in living cells using digitized GFP imaging and FRET microscopy. Methods Cell Biol. 1999;58:293-314.
25. Ono K, Han J. The p38 signal transduction pathway: activation and function. Cell Signal. 2000;12:1-13.
26. Soulet F, Bailly K, Roga S, Lavigne AC, Amalric F, Bouche G. Exogenously added fibroblast growth factor 2 (FGF-2) to NIH3T3 cells interacts with nuclear ribosomal S6 kinase 2 (RSK2) in a cell cycle-dependent manner. J Biol Chem. 2005;280:25604-25610.
27. Saito Y, Haendeler J, Hojo Y, Yamamoto K, Berk BC. Receptor heterodimerization: essential mechanism for platelet-derived growth factor-induced epidermal growth factor receptor transactivation. Mol Cell Biol. 2001;21:6387-6394.
28. Graves LM, Han J, Earp HS 3rd. Transactivation of the EGF Receptor: is the PDGF receptor an unexpected accomplice? Mol Interv. 2002;2:208-212.
29. Hooshmand-Rad R, Claesson-Welsh L, Wennstrom S, Yokote K, Siegbahn A, Heldin CH. Involvement of phosphatidylinositide 3′-kinase and Rac in platelet-derived growth factor-induced actin reorganization and chemotaxis. Exp Cell Res. 1997;234:434-441.
30. Hunter T. Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell. 1995;80:225-236.
31. Pietras K, Sjöblom T, Rubin K, Heldin CH, Östman A. PDGF receptors as cancer drug targets. Cancer Cell. 2003;3:439-443.
32. Battegay EJ, Rupp J, Iruela-Arispe L, Sage EH, Pech M. PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors. J Cell Biol. 1994;125:917-928.
33. Langley RR, Fan D, Tsan RZ, et al. Activation of the platelet-derived growth factor-receptor enhances survival of murine bone endothelial cells. Cancer Res. 2004;64:3727-3730.
34. Facchiano A, De Marchis F, Turchetti E, et al. The chemotactic and mitogenic effects of platelet-derived growth factor-BB on rat aorta smooth muscle cells are inhibited by basic fibroblast growth factor. J Cell Sci. 2000;113:2855-2863.
35. Millette E, Rauch BH, Defawe O, Kenagy RD, Daum G, Clowes AW. Platelet-derived growth factor-BB-induced human smooth muscle cell proliferation depends on basic FGF release and FGFR-1 activation. Circ Res. 2005;96:172-179.
36. Hamilton TG, Klinghoffer RA, Corrin PD, Soriano P. Evolutionary divergence of platelet-derived growth factor alpha receptor signaling mechanisms. Mol Cell Biol. 2003;23:4013-4025.
37. Cao R, Brakenhielm E, Pawliuk R, et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med. 2003;9:604-613.
38. Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res. 2005;65:3967-3979.